372 related articles for article (PubMed ID: 29581794)
1. Noninvasive Glioblastoma Testing: Multimodal Approach to Monitoring and Predicting Treatment Response.
Verduin M; Compter I; Steijvers D; Postma AA; Eekers DBP; Anten MM; Ackermans L; Ter Laan M; Leijenaar RTH; van de Weijer T; Tjan-Heijnen VCG; Hoeben A; Vooijs M
Dis Markers; 2018; 2018():2908609. PubMed ID: 29581794
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.
Kim JY; Gatenby RA
Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831
[TBL] [Abstract][Full Text] [Related]
3. Neuroimaging: diagnosis and response assessment in glioblastoma.
Clarke JL; Chang SM
Cancer J; 2012; 18(1):26-31. PubMed ID: 22290254
[TBL] [Abstract][Full Text] [Related]
4. Taming Glioblastoma in "Real Time": Integrating Multimodal Advanced Neuroimaging/AI Tools Towards Creating a Robust and Therapy Agnostic Model for Response Assessment in Neuro-Oncology.
de Godoy LL; Chawla S; Brem S; Mohan S
Clin Cancer Res; 2023 Jul; 29(14):2588-2592. PubMed ID: 37227179
[TBL] [Abstract][Full Text] [Related]
5. Radiomics for precision medicine in glioblastoma.
Aftab K; Aamir FB; Mallick S; Mubarak F; Pope WB; Mikkelsen T; Rock JP; Enam SA
J Neurooncol; 2022 Jan; 156(2):217-231. PubMed ID: 35020109
[TBL] [Abstract][Full Text] [Related]
6. Radiomics signature for temporal evolution and recurrence patterns of glioblastoma using multimodal magnetic resonance imaging.
Chougule T; Gupta RK; Saini J; Agrawal S; Gupta M; Vakharia N; Singh A; Patir R; Vaishya S; Ingalhalikar M
NMR Biomed; 2022 Mar; 35(3):e4647. PubMed ID: 34766380
[TBL] [Abstract][Full Text] [Related]
7. Tumor treating fields in the management of Glioblastoma: opportunities for advanced imaging.
Soni VS; Yanagihara TK
Cancer Imaging; 2019 Nov; 19(1):76. PubMed ID: 31783910
[TBL] [Abstract][Full Text] [Related]
8. Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.
Shiroishi MS; Boxerman JL; Pope WB
Neuro Oncol; 2016 Apr; 18(4):467-78. PubMed ID: 26364321
[TBL] [Abstract][Full Text] [Related]
9. New imaging techniques for more effective treatment in glioblastoma.
Fay MF; Martin JH; Rose S
Intern Med J; 2014 Jan; 44(1):5-6. PubMed ID: 24450518
[No Abstract] [Full Text] [Related]
10. Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.
Qin L; Li X; Stroiney A; Qu J; Helgager J; Reardon DA; Young GS
Neuroradiology; 2017 Feb; 59(2):135-145. PubMed ID: 28070598
[TBL] [Abstract][Full Text] [Related]
11. Imaging Genetic Heterogeneity in Glioblastoma and Other Glial Tumors: Review of Current Methods and Future Directions.
Chow D; Chang P; Weinberg BD; Bota DA; Grinband J; Filippi CG
AJR Am J Roentgenol; 2018 Jan; 210(1):30-38. PubMed ID: 28981352
[TBL] [Abstract][Full Text] [Related]
12. [Targeted therapy in glioblastoma: update and perspectives].
Idbaih A; Duran-Peña A; Alentorn A
Bull Acad Natl Med; 2015 Nov; 199(8-9):1323-1329. PubMed ID: 29874421
[TBL] [Abstract][Full Text] [Related]
13. Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma.
Li Y; Ma Y; Wu Z; Xie R; Zeng F; Cai H; Lui S; Song B; Chen L; Wu M
Front Immunol; 2021; 12():790674. PubMed ID: 34899760
[TBL] [Abstract][Full Text] [Related]
14. Assessing and monitoring intratumor heterogeneity in glioblastoma: how far has multimodal imaging come?
Boonzaier NR; Piccirillo SG; Watts C; Price SJ
CNS Oncol; 2015; 4(6):399-410. PubMed ID: 26497327
[TBL] [Abstract][Full Text] [Related]
15. Management of Glioblastoma, Present and Future.
Oberheim Bush NA; Hervey-Jumper SL; Berger MS
World Neurosurg; 2019 Nov; 131():328-338. PubMed ID: 31658576
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicine and Immunotherapy: A Step Further towards Precision Medicine for Glioblastoma.
Šamec N; Zottel A; Videtič Paska A; Jovčevska I
Molecules; 2020 Jan; 25(3):. PubMed ID: 31979318
[TBL] [Abstract][Full Text] [Related]
17. Understanding and Treating Glioblastoma.
Wick W; Platten M
Neurol Clin; 2018 Aug; 36(3):485-499. PubMed ID: 30072067
[TBL] [Abstract][Full Text] [Related]
18. Pharmacometabolomics Informs Quantitative Radiomics for Glioblastoma Diagnostic Innovation.
Katsila T; Matsoukas MT; Patrinos GP; Kardamakis D
OMICS; 2017 Aug; 21(8):429-439. PubMed ID: 28816643
[TBL] [Abstract][Full Text] [Related]
19. Optic nerve glioblastoma detected by
Rizzo V; Mattoli MV; Trevisi G; Coli A; Calcagni ML; Montano N
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(4):259-260. PubMed ID: 28802548
[No Abstract] [Full Text] [Related]
20. 18F-FCho PET and MRI for the prediction of response in glioblastoma patients according to the RANO criteria.
Bolcaen J; Acou M; Boterberg T; Vanhove C; De Vos F; Van den Broecke C; Van Holen R; Deblaere K; Goethals I
Nucl Med Commun; 2017 Mar; 38(3):242-249. PubMed ID: 27984537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
